Health-care companies ticked up amid deal activity.
CymaBay Therapeutics shares rallied after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.
Obesity drug makers Novo Nordisk and Eli Lilly gave back some of their torrid 2024 gains.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
02-12-24 1841ET